Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition

Wada, Jun; Shintani, Nahoko; Kikutani, Kenji; Nakae, Takashi; Yamauchi, Tatsuya; Takechi, Kazuo

doi:10.1046/j.1365-2249.2001.01499.x

Cited by 29 publications

(20 citation statements)

References 31 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wada et al 62 produced an experimental autoimmune myositis model in SJL/J mice by immunization with rabbit myosin B fraction. The administration of IVIG dose-dependently reduced the incidence of necrotic and inflammatory changes in the skeletal muscle, and decreased the deposition of IgG and C3 in muscle fibers, as well as the elevation of antimyosin B antibody level.…”

Section: Discussionmentioning

confidence: 99%

Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis

Hara

Kinoshita

Saito

et al. 2003

Modern Rheumatology

View full text Add to dashboard Cite

High-dose intravenous immunoglobulin (IVIG) therapy has been effective in treating many autoimmune and systemic inflammatory diseases. In the present prospective study, we evaluated the efficacy of IVIG for patients with polymyositis (PM) and dermatomyositis (DM) refractory to treatment with high-dose corticosteroids. PM/DM was defined as steroid-resistant when the muscle strength of a patient did not improve despite the administration of more than 50 mg prednisolone per day for more than 4 weeks. A total of 12 patients with biopsy-proven, steroidresistant PM/DM received one infusion of polyethylene glycol-treated human IgG at a dose of 0.4 g per kg per day for five successive days. Three of the patients received a second infusion. All patients were followed for up to 3 months after the infusion. Finally, 8 patients (6 PM and 2 DM; 5 men and 3 women) aged 29-67 years (mean 48 years) were analyzed. Their clinical response was assessed by

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis

Hara

Kinoshita

Saito

et al. 2003

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…микроангиопатию, а также при синдроме Гийе-на-Барре и миастении [73]. ВВИГ содержат фракции натуральных анти-тел к целому ряду иммунорегуляторных молекул, интерлейкину-1α (IL-1α) и фактору некроза опу-холи -α (TNFα) [4,12].…”

Section: ввиг: механизмы терапевтических эффектов Therapeutic Effectsunclassified

Intravenous Immunoglobulins: Mechanisms of Therapeutic Effects

Лазанович¹,

Просекова²

2014

Med.Imm.Rus

View full text Add to dashboard Cite

“…Dalakas [31] recently demonstrated that IVIg blocks complement deposition in a mouse model of experimental autoimmune myositis, suggesting a possible mechanism of action for its efficacy in DM.…”

Section: Opinion Statementmentioning

confidence: 99%

Dermatomyositis and polymyositis

Briemberg¹,

Amato

2003

Curr Treat Options Neurol

View full text Add to dashboard Cite

Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies characterized by proximal greater than distal muscle weakness, elevated serum creatine kinase levels, electrophysiologic abnormalities, and inflammation on muscle biopsy. Clinically and electrophysiologically, DM and PM appear very similar, and muscle biopsy is the gold standard for diagnosis. Much of the PM literature based the diagnosis on Bohan and Peter's criteria, which is now obsolete given the advances of immunopathology. As diagnostic criteria for the inflammatory myopathies have been refined, it has become apparent that PM is much less common than previously thought, and, in fact, is probably quite rare. More recent literature, using strict histopathologic criteria for diagnosis of PM, has brought into question previously reported associations. Because of this, the clinical entity of PM is poorly defined. The exact incidence of each is unknown because previous epidemiologic studies often grouped them together, but overall the annual incidence of the inflammatory myopathies is approximately one in 100,000. DM and PM respond to immunomodulating therapies. High-dose oral prednisone is generally accepted first-line therapy. In patients who do not respond adequately to prednisone alone, or in whom prednisone cannot be weaned, methotrexate or azathioprine can be added. In the authors' experience, methotrexate works faster and is more effective than azathioprine. However, because of the increased risk of interstitial lung disease with methotrexate, the authors avoid this in patients with anti-Jo-1 antibodies and, obviously, in patients who already have pulmonary disease. If patients do not respond adequately to the combination of prednisone and methotrexate or azathioprine, a trial of intravenous immunoglobulin is administered.

show abstract

Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition

Cited by 29 publications

References 31 publications

Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis

Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis

Intravenous Immunoglobulins: Mechanisms of Therapeutic Effects

Dermatomyositis and polymyositis

Contact Info

Product

Resources

About